By Scientia Professor Gregory John Dore

Books

, 2009, Hepatitis C: An Expanding Perspective, Dore GJ; Dore G; Lloyd AROLA, (eds.), IP Communications, East Hawthorn

Book Chapters

Hajarizadeh B; Martinello M; Dore G, 2021, 'HCV Elimination in Australia', in Hepatitis C: Epidemiology, Prevention and Elimination Volume 1, Springer, https://doi.org/10.1007/978-3-030-64649-3_11

Dore GJ; Martinello M, 2020, 'Global elimination of hepatitis C virus by 2030: The optimistic view', in Clinical Dilemmas in Viral Liver Disease Second Edition, pp. 238 - 243, http://dx.doi.org/10.1002/9781119533481.ch40

Martinello M; Hajarizadeh B; Grebely J; Matthews G; Dore G, 2019, 'Cure and Control: What Will It Take to Eliminate HCV?', in Sofia M (ed.), HCV: The Journey from Discovery to a Cure: Volume II, Springer International Publishing, pp. 447 - 490, http://dx.doi.org/10.1007/7355_2018_56

Martinello MK; Grebely J; Dore G, 2017, 'Protease, polymerase and assembly inhibitors for the treatment of hepatitis C virus infection', in Kucers' The Use of Antibiotics A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition - Three Volume Set, CRC Press

Thein H-H; Dore GJ, 2010, 'Cognitive Function, Mood and Health-Related Quality of Life in Hepatitis C Virus-Infected Individuals', in Handbook of Disease Burdens and Quality of Life Measures, Springer New York, pp. 3299 - 3326, http://dx.doi.org/10.1007/978-0-387-78665-0_191

Grebely J; Dore GJ, 2009, 'Acute hepatitis C infection', in Dore G; Temple-Smith M; Lloyd A (ed.), Hepatitis C: An Expanding Perspective, IP Communications, East Hawthorn, pp. 230 - 253

Boesecke C; Dore GJ; Cooper DA, 2009, 'AIDS: Clinical Manifestations', in Encyclopedia of Life Sciences (eLS), John Wiley & Sons, Ltd., Chichester, pp. 1 - 10, http://dx.doi.org/10.1002/9780470015902.a0002237.pub2

Dore GJ; Temple-Smith M; Lloyd AROLA, 2009, 'Future challenges for hepatitis C', in Dore G; Temple-Smith M; Lloyd A (ed.), Hepatitis C: An Expanding Perspective, IP Communications, East Hawthorn, pp. 433 - 452, http://www.ipcommunications.com.au/

Matthews G; Dore GJ, 2009, 'HIV and hepatitis C co-infection', in Dore G; Temple-Smith M; Lloyd A (ed.), Hepatitis C: An Expanding Perspective, IP Communications, East Hawthorn, pp. 308 - 329

Loveday S; Dore GJ, 2009, 'Improving quality of life for people with hepatitis C', in Dore G; Temple-Smith M; Lloyd A (ed.), Hepatitis C: An Expanding Perspective, IP Communications, East Hawthorn, pp. 172 - 180

Dore GJ, 2009, 'Initial assessment and clinical monitoring of people with hepatitis C', in Dore G; Temple-Smith M; Lloyd A (ed.), Hepatitis C: An Expanding Perspective, IP Communications, East Hawthorn, pp. 156 - 169

Thein HH; Dore GJ, 2009, 'Natural history of hepatitis C virus infection', in Dore G; Temple-Smith M; Lloyd A (ed.), Hepatitis C: An Expanding Perspective, IP Communications, East Hawthorn, pp. 76 - 89

Dore GJ, 2009, 'Therapy decision-making for people with chronic hepatitis C', in Dore G; Temple-Smith M; Lloyd A (ed.), Hepatitis C: An Expanding Perspective, IP Communications, East Hawthorn, pp. 181 - 191

Nguyen VT; Dore GJ, 2008, 'Prevalence and epidemiology of hepatitis B', in Matthews G; Robotin M (ed.), B positive: All you wanted to know about hepatitis B: A guide for primary care providers, Australasian Society for HIV Medicine (ASHM), Darlinghurst, Australia, pp. 13 - 23, http://www.ashm.org.au/images/publications/monographs/b%20positive/b_positive-all_you_wanted_to_know.pdf

Dore GJ; Cooper DA, 2003, 'AIDS : Clinical Manifestations', in , Wiley, http://dx.doi.org/10.1038/npg.els.0002237

Dore GJ, 2001, 'Initial assessment and clinical monitoring of people with hepatitis C', in Crofts N; Dore G; Locarnini S (ed.), Hepatitis C: An Australian Perspective, IP Communications, Melbourne, pp. 129 - 139

Dore GJ, 2001, 'Natural history of hepatitis C infection', in Crofts N; Dore G; Locarnini S (ed.), Hepatitis C: An Australian Perspective, IP Communications, Melbourne, pp. 82 - 100

Dore GJ, 2001, 'Theapy decision-making for people with chronic hepatitis C', in Crofts N; Dore G; Locarnini S (ed.), Hepatitis C: An Australian Perspective, IP Communications, Melbourne, pp. 172 - 182

Correll PK; MacDonald MA; Dore GJ, 2000, 'Hepatitis C infection in indigenous communities in Australia', in Hepatitis C: Informing Australia`s Response, Commonwealth Department of Health and Aged Care, Canberra, pp. 47 - 60

Dore GJ, 2000, 'Natural history of hepatitis C virus infection', in Hepatitis C: Informing Australia`s Response, Commonwealth Department of Health and Aged Care, Canberra, pp. 95 - 118

MacDonald MA; Correll PK; Dore GJ, 2000, 'Occupational exposure to hepatitis C in health care settings', in Hepatitis C: Informing Australia`s Response, Commonwealth Department of Health and Aged Care, Canberra, pp. 119 - 135

Journal articles

Masters J; Goodman-Meza D; Russell D; Marks L; McCreary E; Jacka B; Seear K; Davis JS; Matthews G; Martinello M; Tong SYC; Dore GJ, 2025, 'Bacterial and fungal infections in persons who inject drugs.', Clin Microbiol Rev, pp. e0016223, http://dx.doi.org/10.1128/cmr.00162-23

Goodman-Meza D; Weiss RE; Poimboeuf ML; Feng J; Vijayan T; Martinello M; Matthews GV; Dore GJ, 2025, 'Comparative Effectiveness of Long-Acting Lipoglycopeptides vs Standard-of-Care Antibiotics in Serious Bacterial Infections', JAMA Network Open, 8, http://dx.doi.org/10.1001/jamanetworkopen.2025.11641

Sazzad HMS; Li H; Hajarizadeh B; Horsburgh BA; Grebely J; Dore GJ; Bull RA; Lloyd AR; Rodrigo C, 2025, 'Estimating the impact of direct acting antiviral therapy on the prevalence of hepatitis C virus infection using phylogenetics', Virus Research, 355, http://dx.doi.org/10.1016/j.virusres.2025.199566

Masters J; Jacka B; Barault M; Goodman-Meza D; Russell D; Matthews GV; Dore GJ; Valerio H; Martinello M, 2025, 'Incidence, Patient-Directed Discharge, Readmission, and Mortality Among People Hospitalized With Injecting-Related Infection: A Population-Based Linkage Study', Open Forum Infectious Diseases, 12, http://dx.doi.org/10.1093/ofid/ofaf257

Jacka BP; Cheng QL; Schiavone B; Darley DR; Kelleher AD; Dore GJ; Matthews GV, 2025, 'Trajectories of Health-Related Quality of Life 2 Years After Mild/Moderate Severe Acute Respiratory Syndrome Coronavirus 2 Infection in the Pre-Omicron Era', Open Forum Infectious Diseases, 12, http://dx.doi.org/10.1093/ofid/ofaf142

Tillakeratne S; Valerio H; Alavi M; Hajarizadeh B; Martinello M; George J; Matthews G; Grebely J; Pearson SA; Dore GJ, 2025, 'Trends in cause-specific mortality among people with hepatitis C virus in New South Wales, Australia', International Journal of Drug Policy, 139, http://dx.doi.org/10.1016/j.drugpo.2025.104790

Carson JM; Dore GJ, 2025, 'Learning From the Gaps: Rethinking Hepatitis C Virus Retreatment for People Who Inject Drugs.', Clin Infect Dis, http://dx.doi.org/10.1093/cid/ciaf083

Artenie A; Trickey A; Looker KJ; Stone J; Lim AG; Fraser H; Degenhardt L; Dore GJ; Grebely J; Cunningham EB; Hazarizadeh B; Low-Beer D; Luhmann N; Webb P; Hickman M; Vickerman P, 2025, 'Global, regional, and national estimates of hepatitis C virus (HCV) infection incidence among people who inject drugs and number of new annual HCV infections attributable to injecting drug use: a multi-stage analysis', Lancet Gastroenterology and Hepatology, 10, pp. 315 - 331, http://dx.doi.org/10.1016/S2468-1253(24)00442-4

Wheeler A; Masters J; Pradhan A; Roth JM; Degenhardt L; Dore GJ; Matthews GV; Cunningham EB; Peacock A; Colledge-Frisby S; Grebely J; Hajarizadeh B; Martinello M, 2025, 'Prevalence of Injection-Related Bacterial and Fungal Infection Among People Who Inject Drugs: A Systematic Review and Meta-analysis', Open Forum Infectious Diseases, 12, http://dx.doi.org/10.1093/ofid/ofaf108

Stevens A; Lafferty L; Treloar C; Cunningham EB; Dore GJ; Grebely J; Marshall AD, 2025, 'Acceptability of hepatitis C testing using point-of-care testing and dried blood spot collection among people at risk of hepatitis C infection', International Journal of Drug Policy, 137, pp. 104720 - 104720, http://dx.doi.org/10.1016/j.drugpo.2025.104720

Dore GJ, 2025, 'Monitoring hepatitis C elimination among people who inject drugs: A broader approach is required', International Journal of Drug Policy, 137, http://dx.doi.org/10.1016/j.drugpo.2025.104712

Young C; Singh M; Jackson KJL; Field MA; Peters TJ; Angioletti-Uberti S; Frenkel D; Ravishankar S; Gupta M; Wang JJ; Agapiou D; Faulks ML; Al-Eryani G; Luciani F; Gordon TP; Reed JH; Danta M; Carr A; Kelleher AD; Dore GJ; Matthews G; Brink R; Bull RA; Suan D; Goodnow CC, 2025, 'A triad of somatic mutagenesis converges in self-reactive B cells to cause a virus-induced autoimmune disease', Immunity, 58, pp. 412 - 430.e10, http://dx.doi.org/10.1016/j.immuni.2024.12.011

Hiebert-Suwondo L; Manning J; Tohme RA; Buti M; Kondili LA; Spearman CW; Prabdial-Sing N; Turnier V; Lazarus JV; Waked I; Ward JW; Miranda A; Sugiyama A; Hajarizadeh B; Varaldo C; Thomas C; Muñoz C; Leeman D; Dore G; Desalegn H; Aberra H; Cheinquer H; Qureshi H; Ivanchuk I; Grebely J; García-Samaniego J; Tanaka J; Tint KS; Poovorawan K; De Feo ME; Sonderup M; Aleksandrova M; Ali M; Hassany M; Marinho R; Hamid S; Punpetch S; Naing TS; Tanaka-Kumadai Y; Lim YS; Nartey Y, 2025, 'A 2024 global report on national policy, programmes, and progress towards hepatitis B elimination: findings from 33 hepatitis elimination profiles', The Lancet Gastroenterology and Hepatology, http://dx.doi.org/10.1016/S2468-1253(25)00069-X

Byrne CD; Dore GJ, 2025, 'Metabolic dysfunction-associated steatotic liver disease a multisystem disease: Assessing the cost effectiveness of pharmacotherapies', Journal of Hepatology, http://dx.doi.org/10.1016/j.jhep.2025.02.001

Ivancovsky Wajcman D; Nicolàs A; Picchio CA; van Selm L; Dusheiko G; Younossi ZM; Dillon JF; Alqhatani SA; Razavi H; Colombo MG; Kautz A; Dore GJ; Lazarus JV, 2025, 'Prioritising viral hepatitis elimination to prevent hepatocellular carcinoma: A public health approach for effective preventive hepatology', JHEP Reports, pp. 101436 - 101436, http://dx.doi.org/10.1016/j.jhepr.2025.101436

McKetin R; Degan TJ; Saunders L; Nguyen L; Dore G; Shoptaw S; Farrell M; Degenhardt L; Kelly PJ; Turner A; Clare PJ; Dean OM; Arunogiri S; Colledge-Frisby S; Koeijers J; Goodman-Meza D; Sinclair B; Reid D; Hill H; Hayllar J; Christmass M; Cordaro F; Lundin R; Liaw W; Liu D; Holyoak E; Wu BTF; Keygan J; Kontogiannis A; Palmer L; Morrison C; Wrobel A; Hyland B; Byrne M; Russell S; Zahra E; Berk M, 2024, 'A phase 3 randomised double-blind placebo-controlled trial of mirtazapine as a pharmacotherapy for methamphetamine use disorder: a study protocol for the Tina Trial', Trials, 25, http://dx.doi.org/10.1186/s13063-024-08238-y

Martinello M; Carson JM; Post JJ; Finlayson R; Baker D; Read P; Shaw D; Bloch M; Doyle J; Hellard M; Filep E; Hosseini-Hooshyar S; Dore GJ; Matthews GV, 2024, 'Control and Elimination of Hepatitis C Virus Among People With HIV in Australia: Extended Follow-up of the CEASE Cohort (2014-2023)', Open Forum Infectious Diseases, 11, http://dx.doi.org/10.1093/ofid/ofae665

Phetsouphanh C; Jacka B; Ballouz S; Jackson KJL; Wilson DB; Manandhar B; Klemm V; Tan HX; Wheatley A; Aggarwal A; Akerman A; Milogiannakis V; Starr M; Cunningham P; Turville SG; Kent SJ; Byrne A; Brew BJ; Darley DR; Dore GJ; Kelleher AD; Matthews GV, 2024, 'Improvement of immune dysregulation in individuals with long COVID at 24-months following SARS-CoV-2 infection', Nature Communications, 15, http://dx.doi.org/10.1038/s41467-024-47720-8

Bah R; Sheehan Y; Li X; Dore GJ; Grebely J; Lloyd AR; Hajarizadeh B; Bah R; Li C; Byrne M; Butler T; Musarurwa B; Hooshmand E; Simpson A; Alrayyani M; Price N; Groom M, 2024, 'Prevalence of blood-borne virus infections and uptake of hepatitis C testing and treatment in Australian prisons: the AusHep study', Lancet Regional Health Western Pacific, 53, http://dx.doi.org/10.1016/j.lanwpc.2024.101240

MacLachlan JH; Allard N; Tran L; Savage A; Adamson E; Price V; Pearce C; Dore GJ; Cowie BC, 2024, 'Uptake of guideline-based testing for chronic viral hepatitis in Australian primary care: retrospective analysis of electronic medical record data', Australian Journal of Primary Health, 30, http://dx.doi.org/10.1071/PY24143

Marshall AD; Conway A; Cunningham EB; Valerio H; Silk D; Alavi M; Tillakeratne S; Wade A; Lam T; Zohrab K; Dunlop A; Connelly C; Cock V; Burns C; Henderson C; Christmass M; Dore GJ; Grebely J, 2024, 'A Pilot Randomised Controlled Trial Involving Financial Incentives to Facilitate Hepatitis C Treatment Uptake Among People Who Inject Drugs: ETHOS Engage Study', Viruses, 16, http://dx.doi.org/10.3390/v16111763

Ryan H; Dore GJ; Grebely J; Byrne M; Cunningham EB; Martinello M; Lloyd AR; Hajarizadeh B, 2024, 'Hepatitis C treatment outcome among people in prison: The SToP-C study', Liver International, 44, pp. 2996 - 3007, http://dx.doi.org/10.1111/liv.16074

Tillakeratne S; Pearson SA; Alavi M; Hajarizadeh B; Martinello M; Law M; George J; Amin J; Matthews G; Grebely J; Dore GJ; Valerio H, 2024, 'Trends in viral hepatitis liver-related morbidity and mortality in New South Wales, Australia', Lancet Regional Health Western Pacific, 51, http://dx.doi.org/10.1016/j.lanwpc.2024.101185

Maher L; Wand H; Heard S; Starr M; Zolala F; Kemp R; Cunningham P; Drummer H; Hellard M; Kaldor J; Dore G, 2024, 'Utilising integrated bio-behavioural surveillance (IBBS) to investigate declining hepatitis C antibody prevalence among people who inject drugs in the Australian Needle and Syringe Program Survey.', Int J Drug Policy, pp. 104576, http://dx.doi.org/10.1016/j.drugpo.2024.104576

Maher L; Wand H; Heard S; Starr M; Zolala F; Kemp R; Cunningham P; Drummer H; Hellard M; Kaldor J; Dore G, 2024, 'Utilising Integrated Bio-behavioural Surveillance (IBBS) to investigate declining hepatitis C antibody prevalence among people who inject drugs in the Australian Needle and Syringe Program Survey', International Journal of Drug Policy, 131, http://dx.doi.org/10.1016/j.drugpo.2024.104545

Marshall AD; Rance J; Dore GJ; Grebely J; Treloar C, 2024, 'Applying a stigma and time framework to facilitate equitable access to hepatitis C care among women who inject drugs: The ETHOS Engage Study', International Journal of Drug Policy, 129, http://dx.doi.org/10.1016/j.drugpo.2024.104477

Valerio H; Alavi M; Marshall AD; Hajarizadeh B; Amin J; Law M; Tillakeratne S; George J; Degenhardt L; Grebely J; Matthews GV; Dore GJ, 2024, 'Factors associated with hepatitis C treatment uptake among females of childbearing age in New South Wales, Australia: A population-based study', Drug and Alcohol Review, 43, pp. 1080 - 1092, http://dx.doi.org/10.1111/dar.13688

Murdock NA; Alajaji NE; Schaefer R; Boone CA; Campo RE; Dore GJ; Gandhi M; Gorospe JR; Gulick RM; Hodder SL; Liu J; Rhee MS; Rooney JF; Vannappagari V; Wilkin T; Miller V, 2024, 'Long-acting HIV Treatments: Study Design, Logistics, and Access', Open Forum Infectious Diseases, 11, http://dx.doi.org/10.1093/ofid/ofae337

Back to profile page